
30P: Uncommon EGFR Kinase Domain Mutations and Responses to EGFR Inhibitors: A Systematic Review

1. Oncology Department, University Hospital Geneva, Switzerland ; 2. Division of Medical Oncology, Mayo Clinic, Rochester, USA ; 3. Portsmouth Hospitals University NHS Trust, Portsmouth, UK ; 4. Department of Thoracic Head and Neck Medical Oncology, MD Anderson Cancer Center, Houston, USA.


Introduction

Uncommon EGFR mutations represent a rare Non-small-Cell of Cancer Lung subgroup (NSCLC). Data on the efficacy of different generations of tyrosine kinase inhibitors (TKIs) in rare mutations is limited to mostly these retrospective small cohorts, as these patients were usually excluded from clinical trials.

> Patients with EGFR-mutant NSCLC



10-15% Uncommon EGFR Mutations (= other than ex20ins or T790M)



Hôpitaux Universitaires Genève


Reference: . Robichaux JP, et al. Nature 2021;597:732-7

Corresponding authors: <u>maxime.borgeaud@hug.ch;</u> alfredo.addeo@hug.ch

The presenter declares no conflict of interest related to this work. This study received no fundings.

Maxime Borgeaud¹, Kaushal Parikh², Giuseppe Luigi Banna³, Floryane Kim¹, Timothée Olivier¹, Xiuning Le⁴, Alfredo Addeo¹

Results



Single Uncommon Mutations

Each bubble represents the response rate for a mutation (color-code) with response rate and number of patients (n). The size of each bubble is proportional to the number of patients


Response Rates by MDACC - structure-based classification¹

Generation TKI	1 st	2 nd
(Uncommon) Classical-like mutations (N=343)	35.4% (95%CI: 27.2-44.2%)	51.9% (95%CI: 44.4-59.3%
PACC mutations (N=811)	37.2% (95%CI: 32.4-42.1%)	59.6% (95%CI: 54.8-64.3%

This systematic review supports the use of 2nd generation TKI afatinib for G719X, S768I, E709X and L747X mutations, as well as for compound uncommon mutations. For other uncommon mutations such as L861Q, 3rd generation TKI, such as osimertinib, seems a reasonable option could also be considered, considering given its activity and toxicity profile.

3rd 68.3% (95%CI: 50.6-86%) 45.4% (95%CI: 32.5-58.3%)

Uncommon ex19del, ex19delins and ex18del



CONCLUSION

	100% (n=2) 100% (n=1)	
7% (n=8)	83% (n=6)	
78% (n=9) 77% (n=77)	75% (n=4)	
3% (n=52) 2% (n=16)	59% (n=27) 56% (n=16)	
n=6)		
n=10)		common Compound EGFR mutations: G719X - CM with common
3)	•	G719X - CM with uncommon L861Q - CM with common L861Q - CM with uncommon
	•	S768I - CM with common S768I - CM with uncommon
		E709X - CM with common E709X - CM with uncommon

3rd Generation TKI

o (n=3)	100% (n=2)
CE E0 / (
65.5% (n=29)		
		Lincommon ov10dol, ov10doling and ov19dol
		Uncommon ex19del, ex19delins and ex18del E709-T710delinsD in exon 18
		 ex19delins ex19ins
		 uncommon ex19del
	0% (n=3)	
KI	3rd Generation TKI	